Your browser doesn't support javascript.
loading
Do all prostate cancer patients want, and experience shared decision making prior to curative treatment?
Otrebski Nilsson, Mona; Aas, Kirsti; Myklebust, Tor Å; Gjelsvik, Ylva Maria; Haug, Erik Skaaheim; Fosså, Sophie D; Johannesen, Tom Børge.
Afiliación
  • Otrebski Nilsson M; Cancer Registry of Norway, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway. moni@kreftregisteret.no.
  • Aas K; Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Urology, Akershus University Hospital, Lørenskog, Norway.
  • Myklebust TÅ; Cancer Registry of Norway, Oslo, Norway; Department of Research, Møre and Romsdal Hospital Trust, Ålesund, Norway.
  • Gjelsvik YM; Cancer Registry of Norway, Oslo, Norway.
  • Haug ES; Cancer Registry of Norway, Oslo, Norway; Department of Urology Vestfold Hospital Trust, Tønsberg, Norway; Institute of Cancer Genomics and Informatics Oslo University Hospital, Oslo, Norway.
  • Fosså SD; National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital, Oslo, Norway.
  • Johannesen TB; Cancer Registry of Norway, Oslo, Norway.
Scand J Urol ; 58: 133-140, 2023 Dec 20.
Article en En | MEDLINE | ID: mdl-38116675
ABSTRACT

OBJECTIVE:

In comparable men with non-metastatic prostate cancer, radical prostatectomy (RP), radiotherapy (RAD) and active surveillance (AS) are treatment options with similar survival rates, but different side-effects. Healthcare professionals consider pretreatment shared decision making (SDM) to be an essential part of medical care, though the patients' view about SDM is less known. In this article, we explore prostate cancer (PCa) patients' SDM wish (SDMwish), and experiences (SDMexp).  Material and

methods:

This is a registry-based survey performed by the Cancer Registry of Norway (2017-2019). One year after diagnosis, 5,063 curatively treated PCa patients responded to questions about their pre-treatment wish and experience regarding SDM. Multivariable analyses identified factors associated with SDM. Statistical significance level p < 0.05. 

Results:

Overall, 78% of the patients wished to be involved in SDM and 83% of these had experienced SDM. SDMwish and SDMexp was significantly associated with decreasing age, increasing education, and living with a partner. Compared with the RP group, the probability of SDMwish and SDMexp was reduced by about 40% in the RAD and the AS groups. 

Conclusion:

Three of four curatively treated PCa wanted to participate in SDM, and this wish was met in four of five men. Younger PCa patients with higher education in a relationship, and opting for RP, wanted an active role in SDM, and experienced being involved. Effective SDM requires the responsible physicians' attention to the individual patients' characteristics and needs.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Toma de Decisiones Conjunta Límite: Humans / Male Idioma: En Revista: Scand J Urol Año: 2023 Tipo del documento: Article País de afiliación: Noruega

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Toma de Decisiones Conjunta Límite: Humans / Male Idioma: En Revista: Scand J Urol Año: 2023 Tipo del documento: Article País de afiliación: Noruega